Exelixis | EXEL - Debt


Exelixis reported $169.54M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Exelixis USD 169.54M 3.5M Mar/2026
Genmab DKK 148M 5M Jun/2025
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.73B 231M Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sanofi EUR 20.02B 1.73B Mar/2026
Takeda JPY 4.94T 58.13B Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Xencor USD 175.16M 12.58M Mar/2026